about
Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy miceA splice site mutation in laminin-α2 results in a severe muscular dystrophy and growth abnormalities in zebrafishLaminins of the neuromuscular system.Laminin regulates postnatal oligodendrocyte production by promoting oligodendrocyte progenitor survival in the subventricular zone.The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.The integrin family of cell adhesion molecules has multiple functions within the CNS.Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality.Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stagesLaminins and their receptors in Schwann cells and hereditary neuropathies.Polarization and myelination in myelinating glia.The congenital muscular dystrophies: recent advances and molecular insights.Physiological and pathological implications of laminins: from the gene to the protein.Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophyKu70 regulates Bax-mediated pathogenesis in laminin-alpha2-deficient human muscle cells and mouse models of congenital muscular dystrophy.Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy.Biological role of dystroglycan in Schwann cell function and its implications in peripheral nervous system diseases.Overview: studying integrins in vivo.Gene expression profiling of diaphragm muscle in alpha2-laminin (merosin)-deficient dy/dy dystrophic mice.Laminin alpha2 chain-positive vessels and epidermal growth factor in lung neuroendocrine carcinoma: a model of a novel cooperative role of laminin-2 and epidermal growth factor in vessel neoplastic invasion and metastasisExtracellular cues influencing oligodendrocyte differentiation and (re)myelinationAdhesion G-protein coupled receptors and extracellular matrix proteins: Roles in myelination and glial cell development.Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A).Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy.Laminin {alpha}1 chain corrects male infertility caused by absence of laminin {alpha}2 chainTransgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.Regulation of the blood-testis barrier by a local axis in the testis: role of laminin α2 in the basement membrane.Basement Membrane Laminin α2 Regulation of BTB Dynamics via Its Effects on F-Actin and Microtubule Cytoskeletons Is Mediated Through mTORC1 Signaling.Schwann cell myelination occurred without basal lamina formation in laminin alpha2 chain-null mutant (dy3K/dy3K) mice.Intraventricular injection of antibodies to beta1-integrins generates pressure gradients in the brain favoring hydrocephalus development in rats.Aberrant Caspase Activation in Laminin-α2-Deficient Human Myogenic Cells is Mediated by p53 and Sirtuin Activity.Identification of Two Novel LAMA2 Mutations in a Chinese Patient with Congenital Muscular Dystrophy.Dystroglycan promotes filopodial formation and process branching in differentiating oligodendroglia.Laminin alpha2 is essential for odontoblast differentiation regulating dentin sialoprotein expression.Immunodetection analysis of muscular dystrophies in Mexico.
P2860
Q24602606-65473906-E38B-41DE-A3C8-DEE457D789D3Q27322025-6AF282B7-CE86-48C1-89B3-101F74E2B6ADQ34071971-2F82496C-BD5B-4B6D-A9CB-6BFFE3F638DCQ34282245-6F4A2BAC-1295-4B59-8181-3B69E0E9A441Q34708324-6CAD9AD3-E710-4BB1-A032-1AE717449D8BQ34747530-FB7AACAD-C53B-419C-BC7D-AB6F448E27FEQ35083601-72BD6E4F-30F5-438B-8EDF-A61170842E76Q36118063-4834B6D9-CB55-44F3-AFFD-DE36AFCAA46AQ36164129-376D4B6A-66E1-42BA-BB51-26F4F11161E7Q36530065-DAA16D8C-B810-4ABC-8F30-CA9F676E3251Q36681282-2077B41F-6E9F-4C2B-8A14-5D1EDA780370Q36799398-6E3D925A-59E6-4C16-B09C-0CB301285F5BQ37091285-8993518C-5FA1-4595-9951-65FCCAFBBD51Q37411771-AEAB87D4-218E-4EFA-BCFD-26EC49F7FE28Q37625936-9A088EBB-6BCA-440F-A5A5-E993B515A502Q37772080-727BE672-9D6F-45C8-8985-CEE3D9B63654Q37930504-BC3B37B9-BA99-4912-8200-97571BDE7C10Q38317471-0B9F4C92-01F2-4FF7-BA36-CB87CDBFBE60Q38622731-EB671DA0-F54A-4A71-90B0-8DC79498EFD3Q38789322-393BE83E-FB51-4BDD-A159-E6EB20175E37Q39012388-54E783AC-9D1D-43C0-8515-6FA780E51470Q39120926-9193C186-87FC-4F30-A611-663DDD4C1C73Q39559269-9A541950-5C91-4129-8DF7-045349BD9C33Q40300149-102E9D60-7BC8-4465-A0F2-C30D6E3A22FAQ41086617-6B8219C0-BC58-4FA9-BCE9-022A8E0F4E39Q42489627-910FAA15-0EE1-452F-821E-3E254EDBE996Q42501409-89AF77BD-B99D-4EDB-9E34-D4D8E1390C8BQ42507407-F3A91553-E28B-4534-AEA8-950805931B32Q42507557-C6248452-073C-4FEB-8A4D-CC5F9F37ABD4Q48468837-8EAA7361-5FA1-485E-AE92-0F6B7D801F7AQ49571085-88159B97-08EC-4F20-99A4-25FD76D042B7Q50326365-42831BD9-583B-47C3-A1DB-64641543EA8FQ50507092-EB0593A0-54EF-41FD-94F3-55B46AAA60A2Q52096064-9E160453-C98D-4313-B7EC-C6AB6649287AQ54529815-BA7F8222-3ADE-4D1C-922F-6BF1F725DD97
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Merosin and congenital muscular dystrophy
@ast
Merosin and congenital muscular dystrophy
@en
Merosin and congenital muscular dystrophy
@nl
type
label
Merosin and congenital muscular dystrophy
@ast
Merosin and congenital muscular dystrophy
@en
Merosin and congenital muscular dystrophy
@nl
prefLabel
Merosin and congenital muscular dystrophy
@ast
Merosin and congenital muscular dystrophy
@en
Merosin and congenital muscular dystrophy
@nl
P2093
P2860
P1476
Merosin and congenital muscular dystrophy
@en
P2093
M Nakagawa
Y Miyagoe-Suzuki
P2860
P304
P356
10.1002/(SICI)1097-0029(20000201/15)48:3/4<181::AID-JEMT6>3.0.CO;2-Q
P407
P577
2000-02-01T00:00:00Z